The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer

Background: The safety and efficacy of upfront sunitinib, before nephrectomy in metastatic clear cell renal cancer (mCRC), has not been prospectively evaluated. Methods: Two prospective single-arm phase II studies investigated either two cycles (study A: n = 19) or three cycles (study B: n = 33) of...

Descripción completa

Detalles Bibliográficos
Autores principales: Powles, T., Kayani, I., Blank, C., Chowdhury, S., Horenblas, S., Peters, J., Shamash, J., Sarwar, N., Boletti, K., Sadev, A., O'Brien, T., Berney, D., Beltran, L., Haanen, J., Bex, A.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2011
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082157/
https://www.ncbi.nlm.nih.gov/pubmed/21242586
http://dx.doi.org/10.1093/annonc/mdq564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082157/
https://www.ncbi.nlm.nih.gov/pubmed/21242586
http://dx.doi.org/10.1093/annonc/mdq564

Ejemplares similares